Obesity Clinical Trial
Official title:
Liquid Very-Low-Energy Diets (VLEDs) in Obesity Treatment. Effects of Re-Feeding Duration On Weight Maintenance, Eating Behaviour and Health-Related Quality of Life
The primary objective of the study is to test the hypothesis that prolonged re-feeding after VLED induced weight loss improves weight maintenance and eating behaviour
VLED program:
During the initial 12 weeks, patients were encouraged to follow a strict liquid
very-low-energy diet (470-820 kcal). They selected and paid themselves for one of the
following commercially available diets; Modifast® (820 kcal), Nutrilett® (560 kcal) or
Cambridgekuren® (470 kcal). Free consumption of non-caloric drinks (<6 kcal/100 g) was
allowed. All patients had scheduled nurse visits at week 0 (baseline), 2, 5, 8, and 12. Body
weight was registered at each visit and patients were given support and counselling to
enhance VLED compliance. Side effects were monitored and a more frequent contact was offered
if needed. All patients were encouraged to be physically active.
Dietary treatment:
Following VLED, dietary treatment advice was given during individual dietician counseling at
nine study visits (week 12, 15, 18, 21, 26, 32, 38, 44, and 52). At week 12, the dietician
assigned patients with ≥10% weight loss to treatment group according to randomization.
Standardized written and oral instructions for one or six week re-feeding were provided;
hence, participants as well as study staff were aware of group assignment. During
re-feeding, ordinary meals were gradually re-introduced and VLED portions removed. Patients
with one week re-feeding (Group 1) (instructed at week 12) started with breakfast for three
days, added lunch (or dinner) the next four days, and thereafter the third meal was
re-introduced and VLED discontinued. Patients with six week re-feeding (Group 6) (instructed
at week 12, 15, and 18) started with one regular meal (patient's choice) for three weeks. A
second meal was added the next three weeks, and at week eight the third meal was
re-introduced and VLED discontinued. For both groups between-meal snacks (e.g. fruit) were
recommended from the completion of the re-feeding periods.
Recommended energy intake was based on an estimated energy requirement minus 30% to achieve
an energy-reduced level. Energy requirement was calculated from the equation of
Harris-Benedict for estimation of basal metabolic rate, adjusted by factor 1.3 for total
energy expenditure (moderate level of physical activity). Recommended energy distribution
for breakfast, lunch and dinner was 20, 35 and 35% of daily energy intake, and 10% from
snacks. Dietary prescriptions followed the Swedish Nutrition Recommendations. All patients
were encouraged to increase their level of physical activity.
Power calculation and randomization:
Sample size calculations were based on data from a similar study. A sample size of 75
patients per treatment arm was derived, assuming 80% power to detect a 4 kg weight loss
difference, SD 7 kg, statistical significance level P<0.05, and 35% dropout between week 12
and 52.
Two-hundred and sixty-nine patients started on the VLED regimen, and were after 12 weeks
eligible for randomization if they had lost ≥10% of initial body weight. The randomization
was stratified by the combination of sex and degree of weight loss (strictly greater than or
less than 17.1% weight loss). Eligible patients were randomly assigned within each of the
four strata to one of the two treatments (one or six weeks re-feeding) in blocks of size
two, with equal allocation of treatments within each block. The randomization list was
generated with a pseudo-random number generator, so that the resulting treatment sequence
was reproducible and unpredictable.
The treatment allocation order was arranged in numbered, sealed envelopes and kept in
separate boxes for each strata. At patient assignment, the envelope next in order was drawn
from the appropriate strata box.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
| Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
| Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
| Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
| Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
| Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
| Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
| Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
| Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
| Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
| Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
| Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
| Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
| Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
| Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
| Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |